It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Subscribe To Our Newsletter & Stay Updated
